When it comes to CBD encapsulation, there are several methods that can be used to create a highly bioaccessible CBD extract. At Elixinol, we offer products that are made with two of these methods: Hemp Extract Liposomes and our Create | Build | Dream CBD Powder Blend Powered by OLEO™, a full spectrum CBD powder.
C | B | D comes in three flavors with three proprietary terpene profiles–each specially formulated to meet your ideal energy levels morning, afternoon, and evening. These single-serving sachets are easy to integrate into your everyday life.
Recently, I sat down with OLEO’s CEO, Skyler Bissell, and COO, Derick Anderson, to talk about how our C | B | D powder is made, and some of the features that make it unique. Let’s dive in.
Chris Husong: Thanks for sitting down with us to take a deep dive into our powdered CBD product. Let’s start by talking about the microencapsulation process, and how this kind of water-soluble CBD is made.
Derick Anderson: Microencapsulation is an older technology that was originally invented for pharmaceutical application to make drugs more bioavailable and bioaccessible.
There are lots of supplements that have different properties, and those maybe aren’t digested the same from person to person, or by the body in general. So the general principle of encapsulation is kind of what it sounds like: you take an active ingredient, and you surround it–encapsulate it–with an inactive ingredient. In our case, we use polysaccharides to do that (complex sugars).
And there are different ways you can accomplish the same thing. Liposomal, in Elixinol’s case, is encapsulation in a liquid form whose application is for liquid beverages.
Alternatively, we do spray-drying encapsulation, which removes the water. The benefit is that you get a more shelf-stable product because you won’t have the same water activity.
It’s more bioaccessible [than a tincture] because you get a uniform particle size and it’s water soluble, so it’s easy for your body to use.
CH: Let’s talk about microencapsulation. Do you consider your process to be nanotechnology?
Skyler Bissell: I would say no. It would be a significant stretch to call any type of powder that simply has a nano-sized particle nanotechnology.
Simply taking a homogenizer, which is largely how you make certain types of liposomes or other liquid emotions and homogenizing the powders or the liquids down to the nanoscale–that’s a bit of a stretch to call that nanotechnology. So the type of technology we’re talking about here is specifically known as microencapsulation.
The main reason it’s called microencapsulation is that the particle size of the resulting powder is on the Micron-scale. So it is 10 microns, approximately, in the resulting powder.
Particle size differs; the liposomal particles, for example, are quite a bit smaller, generally speaking.
CH: OLEO has created a full-spectrum CBD powder for Elixinol, rather than a CBD isolate powder. How does this difference impact the encapsulation process?
DA: It’s essentially the same process, but the full-spectrum CBD is cruder. It’s just a cruder form of the CBD. CBD isolate is CBD that has been refined much more. The full-spectrum requires the same process, more or less; you just need a little bit more binder material for the full-spectrum, because there’s more resinous oil in it that you have to encapsulate.
SB: The process is agnostic to the type of oil. And so you’re always going to be breaking down the particles into one particle of oil that’s coated, as Derek said, in a series of inactive ingredient binders.
You’re still getting your little molecule of full-spectrum oil, with all the benefits that you’re seeking from those terpenes and other cannabinoids are locked inside of that molecule.
CH: So let’s talk about bioaccessibility. We often discuss the bioavailability of our products here at Elixinol. But let’s break down the differences between bioavailability and bioaccessibility.
DA: Bioccessibility is to what extent your body makes use of a nutritional supplement–how much is accessible to your body. So that was measured in our study. The biggest benefit comes from the fact that it’s water soluble with small particle sizes. So with the small particle size, you get more surface area in your GI tract. And then the water-solubility helps it pass through that more quickly.
The net result of those two things is a more bioaccessible product. Another term that’s kind of that’s used ubiquitously with it, but should not be, is bioavailable. Bioavailability is determined by two prongs: bioaccessibility (how much can your body make use of a substance), and then bioactivity (what is actually happening when it goes into your body? What does your body actually do with it?).
We don’t have that second one. That’s a more involved, clinical type of study. But we do have the first prong, which is the bioaccessibility study on our microencapsulated CBD.
CH: Earlier, you mentioned that there are some differences between our Liposome product and our CBD powder. Can you expound on that?
SB: Liposomal encapsulation is very different than microencapsulation. Liposomes are liquid-based; they’re very clearly for liquid formulations. It could be rehydrated into a liquid, but you could not really make a liposome into a powder.
In the end, the customer can choose the right solution for them. And that’s always, I think, the fun part: choose your adventure. Choose the best product for you.
CH: Choose your CBD adventure–I love it. Thanks for taking the time to chat with us about C|B|D Powered by OLEO.